Naotsugu Akashi

Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials

Masayoshi Harigai, Tsutomu Takeuchi, Josef S Smolen et al. · Modern Rheumatology · 2019 · 55 citations · Full text

Medicine, Internal Medicine, Pharmacology +17

Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials

Yoshiya Tanaka, Tatsuya Atsumi, Koichi Amano et al. · Modern Rheumatology · 2017 · 49 citations · Full text

Medicine, Internal Medicine, Pharmacology +13

Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis

Naotsugu Akashi, Isao Matsumoto, Yoko Tanaka et al. · Modern Rheumatology · 2011 · 39 citations

Medicine, Immunology, Pharmacology +17

Long‐term efficacy and safety results from an open‐label phase <scp>III</scp> study (<scp>UNCOVER</scp>‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab

Yoshinori Umezawa, Hitoe Torisu‐Itakura, Yoji Morisaki et al. · Journal of the European Academy of Dermatology and Venereology · 2018 · 38 citations · Full text

Medicine, Dermatology, Pharmacotherapy +10

Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis

Naotsugu Akashi, Isao Matsumoto, Yoko Tanaka et al. · Modern Rheumatology · 2010 · 31 citations

Medicine, Immunology, Pharmacology +17